Rxsight Inc (RXST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rxsight Inc (RXST) has a cash flow conversion efficiency ratio of -0.036x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.54 Million) by net assets ($263.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Rxsight Inc for the company's overall valuation and market capitalisation.
Rxsight Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rxsight Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rxsight Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rxsight Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Rxsight Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
-0.018x |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
0.024x |
|
ODAS Elektrik Uretim Sanayi Ticaret AS
IS:ODAS
|
-0.030x |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
0.052x |
|
Ultra Chip
TWO:3141
|
0.036x |
|
EVI Industries Inc
NYSE MKT:EVI
|
0.007x |
|
Aurora Cannabis Inc
TO:ACB
|
0.030x |
|
LTC Co.Ltd
KQ:170920
|
0.043x |
Annual Cash Flow Conversion Efficiency for Rxsight Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rxsight Inc from 2019 to 2025. View RXST stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.68 Million | $-15.51 Million | -0.056x | +6.62% |
| 2024-12-31 | $281.24 Million | $-16.95 Million | -0.060x | +76.77% |
| 2023-12-31 | $160.36 Million | $-41.59 Million | -0.259x | +60.38% |
| 2022-12-31 | $89.90 Million | $-58.85 Million | -0.655x | -102.41% |
| 2021-12-31 | $138.24 Million | $-44.71 Million | -0.323x | -373.33% |
| 2020-12-31 | $-297.53 Million | $-35.20 Million | 0.118x | -11.27% |
| 2019-12-31 | $-304.61 Million | $-40.62 Million | 0.133x | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more